Home › Companies › HERON THERAPEUTICS INC. › 2024-2025

HERON THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and HERON THERAPEUTICS INC.’s Form 8-K, filed 2025-06-18 (Item 5.07 on EDGAR). Page generated 04 October 2026.

10Reported items
154Asset managers
1,347Fund votes
2025-06-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore HERON THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by HERON THERAPEUTICS INC.

These tallies are HERON THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

HERON THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Mr. Collard	82,777,195	1,274,608	47,119	--	35,904,582	Majority: yes
Elect Director: Dr. Dissanaike	81,364,822	2,625,421	108,679	--	35,904,582	Majority: yes
Elect Director: Mr. Johnson	81,742,495	2,302,736	53,691	--	35,904,582	Majority: yes
Elect Director: Mr. Kaseta	81,849,779	2,202,021	47,122	--	35,904,582	Majority: yes
Elect Director: Mr. Morgan	82,815,802	1,225,808	57,312	--	35,904,582	Majority: yes
Elect Director: Mr. Waage	79,359,803	4,687,202	51,917	--	35,904,582	Majority: yes
Proposal 2: The Company's stockholders ratified the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:	118,578,049	1,033,191	392,264	--	0	Majority: yes
Proposal 3: The Company's stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2024:	79,260,872	3,528,575	1,309,475	--	35,904,582	Majority: yes

Source: HERON THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-18 — read the filing on EDGAR.

How asset managers voted at the HERON THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 154 asset managers that disclosed a HERON THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of HERON THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a nonbinding advisory basis, compensation paid to our Named Executive Officers for the fiscal year ended December 31, 2024.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 79,260,872AGAINST: 3,528,575

HERON THERAPEUTICS INC.’s own tally for this item (“Proposal 3: The Company's stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2024:”): 79,260,872 for, 3,528,575 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 152,563,634 outstanding shares: 52.0% for, 2% against (54.3% of the company cast a for/against vote).

The 151 asset managers below cast 99.2% of the shares they voted on this item FOR (77,306,241 for, 599,325 against).

FOR 99.2%

FOR: 77,306,241 (99.2%)AGAINST: 599,325 (0.8%)

Largest asset managers voting on “To approve, on a nonbinding advisory basis, compensation paid to our Named Executive Officers for the fiscal y” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Rubric Capital Management LP	26,451,914	0	For
Velan Capital Investment Management LP	6,985,744	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	6,637,616	0	For
T. Rowe Price	5,489,826	0	For
Point72	4,575,757	0	For
BlackRock	3,563,082	0	For
PALISADE CAPITAL MANAGEMENT, LP	3,042,656	0	For
Vanguard	2,373,661	0	For
DE Shaw	1,882,136	0	For
State Street	1,877,344	0	For
NEW YORK STATE COMMON RETIREMENT FUND	1,760,045	0	For
Renaissance	1,167,737	0	For
Clearline Capital LP	1,059,911	0	For
Orchard Capital Management, LLC	1,007,846	0	For
Charles Schwab	861,926	0	For
Stonepine Capital Management, LLC	796,100	0	For
Two Sigma	720,435	0	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	677,391	0	For
BRIDGEWAY FUNDS INC	677,391	0	For
Citadel	577,574	0	For
Northern Trust	572,722	0	For
MARSHALL WACE, LLP	562,493	0	For
Goldman Sachs	0	479,569	Against
Equitable	370,043	0	For
Wellington	354,473	0	For

Showing the 25 largest of 151 asset managers. See all 151 in the interactive database.

2. TO APPROVE, ON A NONBINDING ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

1 YEAR 52.5%ONE YEAR 47.3%

The 145 asset managers below cast 100% of the shares they voted on this item FOR (116,748 for, 0 against).

FOR: 116,748 (0.2%)1 YEAR: 36,401,394 (52.5%)ONE YEAR: 32,764,621 (47.3%)1-YEAR: 4,210 (0.0%)3 YEARS: 875 (0.0%)

Largest asset managers voting on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Rubric Capital Management LP	0	0	0	0	1 Year
Velan Capital Investment Management LP	0	0	0	0	One Year
T. Rowe Price	0	0	0	0	One Year
Point72	0	0	0	0	One Year
BlackRock	0	0	0	0	1 Year
PALISADE CAPITAL MANAGEMENT, LP	0	0	0	0	One Year
Vanguard	0	0	0	0	One Year
DE Shaw	0	0	0	0	One Year
State Street	0	0	0	0	One Year
NEW YORK STATE COMMON RETIREMENT FUND	0	0	0	0	1 Year
Renaissance	0	0	0	0	One Year
Clearline Capital LP	0	0	0	0	1 Year
Charles Schwab	0	0	0	0	1 Year
Two Sigma	0	0	0	0	One Year
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
BRIDGEWAY FUNDS INC	0	0	0	0	One Year
Citadel	0	0	0	0	One Year
Northern Trust	0	0	0	0	1 Year
MARSHALL WACE, LLP	0	0	0	0	1 Year
Goldman Sachs	0	0	0	0	One Year
Equitable	0	0	0	0	One Year
Wellington	0	0	0	0	1 Year
NexPoint Advisors, L.P.	0	0	0	0	1 Year
HIGHLAND GLOBAL ALLOCATION FUND	0	0	0	0	1 Year
NEXPOINT ASSET MANAGEMENT, L.P.	0	0	0	0	1 Year

Showing the 25 largest of 145 asset managers. See all 145 in the interactive database.

3. To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Adam Morgan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 82,815,802AGAINST: 1,225,808

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Morgan”): 82,815,802 for, 1,225,808 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 152,563,634 outstanding shares: 54.3% for, 0.9% against (55% of the company cast a for/against vote).

The 39 asset managers below cast 99.8% of the shares they voted on this item FOR (10,441,405 for, 11,502 against).

FOR 99.8%

FOR: 10,441,405 (99.9%)AGAINST: 11,502 (0.1%)

Largest asset managers voting on “To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	2,451,439	For
Vanguard	2,288,078	For
BlackRock	2,224,509	For
BRIDGEWAY FUNDS INC	677,391	For
State Street	589,379	For
Charles Schwab	430,963	For
Equitable	370,043	For
Goldman Sachs	259,932	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	For
Lincoln Financial	161,639	For
Principal Exchange-Traded Funds	109,681	For
Nationwide	100,663	For
AIG/SunAmerica	59,972	For
Pacific Life	53,855	For
Northern Trust	51,094	For
Bridge Builder Trust	50,518	For
Fidelity	47,375	For
John Hancock	44,152	For
Voya	29,992	For
Invesco	25,593	For
Brighthouse	24,515	For
ProShares	23,438	For
MASTER INVESTMENT PORTFOLIO	22,992	For
QUANTITATIVE MASTER SERIES LLC	21,878	For
SEI	20,900	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

4. To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Christian Waage

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 79,359,803AGAINST: 4,687,202

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Waage”): 79,359,803 for, 4,687,202 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 152,563,634 outstanding shares: 52.0% for, 3% against (55% of the company cast a for/against vote).

The 39 asset managers below cast 95% of the shares they voted on this item FOR (9,882,431 for, 570,476 against).

FOR 95%

FOR: 9,882,431 (94.5%)AGAINST: 570,476 (5.5%)

Largest asset managers voting on “To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	2,451,439	0	For
Vanguard	2,288,078	0	For
BlackRock	2,224,509	0	For
BRIDGEWAY FUNDS INC	677,391	0	For
State Street	581,587	7,792	For
Charles Schwab	0	430,963	Against
Equitable	370,043	0	For
Goldman Sachs	259,932	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Lincoln Financial	77,347	84,292	Against
Principal Exchange-Traded Funds	109,681	0	For
Nationwide	100,663	0	For
AIG/SunAmerica	59,972	0	For
Pacific Life	53,855	0	For
Northern Trust	51,094	0	For
Bridge Builder Trust	50,518	0	For
Fidelity	47,375	0	For
John Hancock	44,152	0	For
Voya	29,992	0	For
Invesco	25,593	0	For
Brighthouse	24,515	0	For
ProShares	23,438	0	For
MASTER INVESTMENT PORTFOLIO	0	22,992	Against
QUANTITATIVE MASTER SERIES LLC	21,878	0	For
SEI	20,900	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

5. To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Collard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 82,777,195AGAINST: 1,274,608

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Collard”): 82,777,195 for, 1,274,608 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 152,563,634 outstanding shares: 54.3% for, 0.9% against (55% of the company cast a for/against vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (10,452,907 for, 0 against).

FOR 100%

FOR: 10,452,907 (100.0%)

Largest asset managers voting on “To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	2,451,439	For
Vanguard	2,288,078	For
BlackRock	2,224,509	For
BRIDGEWAY FUNDS INC	677,391	For
State Street	589,379	For
Charles Schwab	430,963	For
Equitable	370,043	For
Goldman Sachs	259,932	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	For
Lincoln Financial	161,639	For
Principal Exchange-Traded Funds	109,681	For
Nationwide	100,663	For
AIG/SunAmerica	59,972	For
Pacific Life	53,855	For
Northern Trust	51,094	For
Bridge Builder Trust	50,518	For
Fidelity	47,375	For
John Hancock	44,152	For
Voya	29,992	For
Invesco	25,593	For
Brighthouse	24,515	For
ProShares	23,438	For
MASTER INVESTMENT PORTFOLIO	22,992	For
QUANTITATIVE MASTER SERIES LLC	21,878	For
SEI	20,900	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

6. To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Johnson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 81,742,495AGAINST: 2,302,736

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Johnson”): 81,742,495 for, 2,302,736 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 152,563,634 outstanding shares: 53.6% for, 2% against (55% of the company cast a for/against vote).

The 39 asset managers below cast 99.9% of the shares they voted on this item FOR (10,451,174 for, 1,733 against).

FOR 99.9%

FOR: 10,451,174 (100.0%)AGAINST: 1,733 (0.0%)

Largest asset managers voting on “To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	2,451,439	For
Vanguard	2,288,078	For
BlackRock	2,224,509	For
BRIDGEWAY FUNDS INC	677,391	For
State Street	589,379	For
Charles Schwab	430,963	For
Equitable	370,043	For
Goldman Sachs	259,932	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	For
Lincoln Financial	161,639	For
Principal Exchange-Traded Funds	109,681	For
Nationwide	100,663	For
AIG/SunAmerica	59,972	For
Pacific Life	53,855	For
Northern Trust	51,094	For
Bridge Builder Trust	50,518	For
Fidelity	47,375	For
John Hancock	44,152	For
Voya	29,992	For
Invesco	25,593	For
Brighthouse	24,515	For
ProShares	23,438	For
MASTER INVESTMENT PORTFOLIO	22,992	For
QUANTITATIVE MASTER SERIES LLC	21,878	For
SEI	20,900	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

7. To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Michael Kaseta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 81,849,779AGAINST: 2,202,021

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Kaseta”): 81,849,779 for, 2,202,021 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 152,563,634 outstanding shares: 53.6% for, 1% against (55% of the company cast a for/against vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (10,452,907 for, 0 against).

FOR 100%

FOR: 10,452,907 (100.0%)

Largest asset managers voting on “To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	2,451,439	For
Vanguard	2,288,078	For
BlackRock	2,224,509	For
BRIDGEWAY FUNDS INC	677,391	For
State Street	589,379	For
Charles Schwab	430,963	For
Equitable	370,043	For
Goldman Sachs	259,932	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	For
Lincoln Financial	161,639	For
Principal Exchange-Traded Funds	109,681	For
Nationwide	100,663	For
AIG/SunAmerica	59,972	For
Pacific Life	53,855	For
Northern Trust	51,094	For
Bridge Builder Trust	50,518	For
Fidelity	47,375	For
John Hancock	44,152	For
Voya	29,992	For
Invesco	25,593	For
Brighthouse	24,515	For
ProShares	23,438	For
MASTER INVESTMENT PORTFOLIO	22,992	For
QUANTITATIVE MASTER SERIES LLC	21,878	For
SEI	20,900	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

8. To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Sharmila Dissanaike, M.D., FACS, FCCM

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 81,364,822AGAINST: 2,625,421

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Dissanaike”): 81,364,822 for, 2,625,421 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 152,563,634 outstanding shares: 53.3% for, 2% against (55% of the company cast a for/against vote).

The 39 asset managers below cast 99.6% of the shares they voted on this item FOR (10,415,395 for, 37,512 against).

FOR 99.6%

FOR: 10,415,395 (99.6%)AGAINST: 37,512 (0.4%)

Largest asset managers voting on “To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	2,451,439	0	For
Vanguard	2,288,078	0	For
BlackRock	2,224,509	0	For
BRIDGEWAY FUNDS INC	677,391	0	For
State Street	589,379	0	For
Charles Schwab	430,963	0	For
Equitable	370,043	0	For
Goldman Sachs	259,932	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Lincoln Financial	161,639	0	For
Principal Exchange-Traded Funds	109,681	0	For
Nationwide	100,663	0	For
AIG/SunAmerica	59,972	0	For
Pacific Life	53,855	0	For
Northern Trust	51,094	0	For
Bridge Builder Trust	50,518	0	For
Fidelity	47,375	0	For
John Hancock	44,152	0	For
Voya	29,992	0	For
Invesco	25,593	0	For
Brighthouse	24,515	0	For
ProShares	23,438	0	For
MASTER INVESTMENT PORTFOLIO	0	22,992	Against
QUANTITATIVE MASTER SERIES LLC	21,878	0	For
SEI	20,900	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

9. TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 118,578,049AGAINST: 1,033,191

HERON THERAPEUTICS INC.’s own tally for this item (“Proposal 2: The Company's stockholders ratified the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:”): 118,578,049 for, 1,033,191 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 152,563,634 outstanding shares: 78% for, 0.7% against (78% of the company cast a for/against vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (10,452,907 for, 0 against).

FOR 100%

FOR: 10,452,907 (100.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR E” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	2,451,439	For
Vanguard	2,288,078	For
BlackRock	2,224,509	For
BRIDGEWAY FUNDS INC	677,391	For
State Street	589,379	For
Charles Schwab	430,963	For
Equitable	370,043	For
Goldman Sachs	259,932	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	For
Lincoln Financial	161,639	For
Principal Exchange-Traded Funds	109,681	For
Nationwide	100,663	For
AIG/SunAmerica	59,972	For
Pacific Life	53,855	For
Northern Trust	51,094	For
Bridge Builder Trust	50,518	For
Fidelity	47,375	For
John Hancock	44,152	For
Voya	29,992	For
Invesco	25,593	For
Brighthouse	24,515	For
ProShares	23,438	For
MASTER INVESTMENT PORTFOLIO	22,992	For
QUANTITATIVE MASTER SERIES LLC	21,878	For
SEI	20,900	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

10. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1-YEAR 99.2%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1-YEAR: 6,637,616 (99.2%)ONE YEAR: 53,163 (0.8%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at HERON THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	0	0	0	1-Year
JPMorgan	0	0	0	0	One Year

Largest HERON THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of HERON THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 152,563,634 shares outstanding at the time of that meeting.

Top HERON THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Rubric Capital Management LP	17.34%
2	Velan Capital Investment Management LP	4.58%
3	ADAGE CAPITAL PARTNERS GP, L.L.C.	4.35%
4	T. Rowe Price	3.60%
5	Point72	3.00%
6	BlackRock	2.34%
7	PALISADE CAPITAL MANAGEMENT, LP	1.99%
8	Vanguard	1.56%
9	DE Shaw	1.23%
10	State Street	1.23%

Reported HERON THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

HERON THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	5.61%	13F
Vanguard Group	5.39%	13F
Point72	3.13%	13F
State Street	2.13%	13F
Geode Capital	2.04%	13F
T. Rowe Price	1.97%	13F
D.E. Shaw	1.96%	13F
Renaissance Technologies	1.49%	13F
Morgan Stanley	1.27%	13F
Millennium Management	0.91%	13F

Percentages above are of 152,563,634 shares outstanding, as reported by HERON THERAPEUTICS INC. on its Form 10-Q dated 2025-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HERON THERAPEUTICS INC.’s 10-Q dated 2025-05-01. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At HERON THERAPEUTICS INC.'s shareholder meeting held 2025-06-12, in the 2024-2025 proxy season, 154 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,347 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a nonbinding advisory basis, compensation paid to our Named Executive Officers… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: HERON THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-18.

HERON THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.